I respectfully disagree with your numbers, your timeline, and the uplisting angle.
My reasoning is laid out in an earlier, EZ to read and understand post based primarily on NOT WHAT I THINK, but words directly from Dr. Mark Williams.
Doc Williams has a PhD and MBA. He's the mastermind of Algernon's repurposed drug strategy for multiple compounds including leading compound NP-120 Ifenprodil.
What Doc Williams stated in the BioPub webcast just 2 DAY AGO is NP-120 has a shot at going straight to market DURING THE PHASE 2 clinical trial. He even stated Algernon has biostatisticians looking at that very possibility.
If that happens there will be no NASDAQ or march to $3, $4, $5, $25...
Algernon will get bought out - PERIOD.
But hey, don't pay me no nevermind. I just go through the information they put forth as respect to what their doing for my investment AND to know what the F*** is actually going on with the company and my money.
News 
Market Data 
Discover 
